Saratin for inhibiting platelet adhesion to collagen
AssigneeMerck & Co., Inc.
InventorsChristopher Barnes, Matthias Frech, Uwe Hofmann, Johannes Gleitz, Wolfgang Strittmatter
Life of this patent
Estimating the term…
Abstract
Use of the polypeptide Saratin for the manufacture of a medicament having the capability to significantly decrease platelet adhesion and platelet accumulation after vascular injuries or endarterectomy. The invention furthermore relates to a novel medical use of Sara tin as an inhibitor of thrombosis and intimal hyperplasia, wherein said polypeptide may be used locally as a topical agent or as a coating on, or otherwise incorporated or associated with medical devices.
Claims19
Use of the polypeptide Saratin for the manufacture of a medicament for inhibiting platelet accumulation after vascular injuries or endarterectomy comprising administering to the vascular tissue a therapeutically effective amount of Saratin which prevents platelet adhesion, thereby inhibiting thrombosis and restenosis.
Device having a surface covered with a hydrogel incorporating an amount of biologically active Saratin therein for local delivery therefrom and means associated with the coating to provide an anti-thrombogenic surface.
A catheter device characterized in that a polymeric material is part of the device and contains Saratin.
A method of treating injured vascular tissue, comprising locally administering to the injured vascular tissue a therapeutically effective, platelet adhesion inhibiting amount of Saratin, thereby treating the injured vascular tissue.
Dependencies are inferred from the claim text.